Hemofiltration reduces the serum priming activity on neutrophil chemiluminescence in septic patients.
暂无分享,去创建一个
G. Camussi | C. Tetta | F. Mariano | G. Triolo | G. Guida
[1] G. Camussi,et al. Role of platelet-activating factor in cardiovascular pathophysiology. , 2000, Physiological reviews.
[2] M. Yaffe,et al. Priming of the neutrophil respiratory burst is species-dependent and involves MAP kinase activation. , 1999, Surgery.
[3] R. Bellomo,et al. Continuous renal replacement therapy in the intensive care unit , 1999, Intensive Care Medicine.
[4] G. Camussi,et al. Production of platelet-activating factor in patients with sepsis-associated acute renal failure. , 1999, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[5] J. De Sutter,et al. Cytokine removal during continuous hemofiltration in septic patients. , 1999, Journal of the American Society of Nephrology : JASN.
[6] John P. Johnson,et al. Diffusive vs. convective therapy: effects on mediators of inflammation in patient with severe systemic inflammatory response syndrome. , 1998, Critical care medicine.
[7] J. Cavaillon,et al. Reduced ex vivo interleukin-8 production by neutrophils in septic and nonseptic systemic inflammatory response syndrome. , 1998, Blood.
[8] W. Silvester,et al. Mediator removal with CRRT: complement and cytokines. , 1997, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[9] C. Ronco,et al. Relevance of platelet-activating factor in inflammation and sepsis: mechanisms and kinetics of removal in extracorporeal treatments. , 1997, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[10] M. Lamy,et al. Sepsis and serum cytokine concentrations. , 1997, Critical care medicine.
[11] J. Cavaillon,et al. Presence of high levels of leukocyte-associated interleukin-8 upon cell activation and in patients with sepsis syndrome , 1997, Infection and immunity.
[12] C. Haslett,et al. Demonstration of reversible priming of human neutrophils using platelet-activating factor. , 1996, Blood.
[13] F. A. Moore,et al. Sequential systemic platelet‐activating factor and interleukin 8 primes neutrophils in patients with trauma at risk of multiple organ failure , 1996, The British journal of surgery.
[14] D. Inthorn,et al. Hemofiltration in human sepsis: evidence for elimination of immunomodulatory substances. , 1995, Contributions to nephrology.
[15] G. Camussi,et al. Septic shock--the unravelling of molecular mechanisms. , 1995, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[16] E. Moore,et al. Postinjury neutrophil priming and activation: an early vulnerable window. , 1995, Surgery.
[17] E. Moore,et al. The postischemic gut serves as a priming bed for circulating neutrophils that provoke multiple organ failure. , 1994, The Journal of trauma.
[18] S. Goldfarb,et al. Proinflammatory cytokines and hemofiltration membranes. , 1994, Journal of the American Society of Nephrology : JASN.
[19] C. Elbim,et al. Differential priming effects of proinflammatory cytokines on human neutrophil oxidative burst in response to bacterial N-formyl peptides , 1994, Infection and immunity.
[20] R. Taylor,et al. Plasma degradation of platelet‐activating factor in severely ill patients with clinical sepsis , 1994, Critical care medicine.
[21] R. Bone,et al. Plasma Cytokine and Endotoxin Levels Correlate with Survival in Patients with the Sepsis Syndrome , 1993, Annals of Internal Medicine.
[22] W. H. Betts,et al. Interleukin-8 primes human neutrophils for enhanced superoxide anion production. , 1993, Immunology.
[23] M. Baggiolini,et al. Activation of neutrophil leukocytes: chemoattractant receptors and respiratory burst 1 , 1993, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[24] R. Bellomo,et al. Continuous veno‐venous hemofiltration with dialysis removes cytokines from the circulation of septic patients , 1993, Critical care medicine.
[25] G. Camussi,et al. Role of α1-proteinase inhibitor in restraining peritoneal inflammation in CAPD patients , 1992 .
[26] W. Knaus,et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. , 1992, Chest.
[27] K. Matsushima,et al. Stimulation and priming of human neutrophils by interleukin-8: cooperation with tumor necrosis factor and colony-stimulating factors. , 1991, Blood.
[28] H. Heuer,et al. Pharmacologic activity of bepafant (WEB 2170), a new and selective hetrazepinoic antagonist of platelet activating factor. , 1990, The Journal of pharmacology and experimental therapeutics.
[29] P. Henson,et al. Binding of platelet activating factor to albumin. , 1990, Biochimica et biophysica acta.
[30] W. Hörl,et al. Neutrophil activation in acute renal failure and sepsis. , 1990, Archives of surgery.
[31] P. Sole. Polymorphonuclear chemiluminescence: Some clinical applications , 1989 .
[32] J. Larrick,et al. Enhancement of neutrophil superoxide production by preincubation with recombinant human tumor necrosis factor. , 1987, Journal of immunology.
[33] J. Lukens,et al. Modulation of neutrophil oxidative responses to soluble stimuli by platelet-activating factor. , 1986, Blood.
[34] B. Dewald,et al. Activation of NADPH oxidase in human neutrophils. Synergism between fMLP and the neutrophil products PAF and LTB4. , 1985, Biochemical and biophysical research communications.
[35] H. Nomura,et al. CV-3988 - a specific antagonist of platelet activating factor (PAF). , 1983, Life sciences.
[36] J. Benveniste,et al. Structural analysis of purified platelet-activating factor by lipases , 1977, Nature.
[37] R. Allen. Phagocytic leukocyte oxygenation activities and chemiluminescence: a kinetic approach to analysis. , 1986, Methods in enzymology.